EPISODE · Apr 9, 2012 · 8 MIN
1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting
from Journal of Clinical Oncology (JCO) Podcast
The CHER-LOB trial is one of several that has demonstrated that adding lapatinib to trastuzumab and chemotherapy improves on the rates of complete pathological response among women receiving neoadjuvant therapy for HER2 positive breast cancer. Because the relationship between pCR and long-term outcomes remains ambiguous, this regimen is not recommended for ordinary use. However, these findings are a powerful support to the hypothesis that dual-modality anti-HER2 therapy is a potent combination.
NOW PLAYING
1 + 1 = 3. Combined Use of Anti-HER2 Agents in the Neoadjuvant Setting
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 19, 2026 ·34m
Feb 18, 2026 ·11m
Feb 11, 2026 ·45m